Psychotic Symptoms Associated with the use of Dopaminergic Drugs, in Patients with Cocaine Dependence or Abuse
- PMID: 27009114
- PMCID: PMC5412693
- DOI: 10.2174/1570159x14666160324144912
Psychotic Symptoms Associated with the use of Dopaminergic Drugs, in Patients with Cocaine Dependence or Abuse
Abstract
Background: In the field of dual diagnosis, physicians are frequently presented with pharmacological questions. Questions about the risk of developing psychotic symptoms in cocaine users who need treatment with dopaminergic drugs could lead to an undertreatment.
Objective: Review the presence of psychotic symptoms in patients with cocaine abuse/dependence, in treatment with dopaminergic drugs.
Methods: Systematic PubMed searches were conducted including December 2014, using the keywords: "cocaine", dopaminergic drug ("disulfuram-methylphenidate-bupropion-bromocriptine-sibutramineapomorphine- caffeine") and ("psychosis-psychotic symptoms-delusional-paranoia"). Articles in English, Spanish, Portuguese, French, and Italian were included. Articles in which there was no history of cocaine abuse/dependence, absence of psychotic symptoms, systematic reviews, and animal studies, were excluded.
Results: 313 papers were reviewed. 7 articles fulfilled the inclusion-exclusion criteria. There is a clinical trial including 8 cocaine-dependent patients using disulfiram in which 3 of them presented psychotic symptoms and 6 case-reports: disulfuram (1), methylphenidate (1), disulfiram with methylphenidate (2), and bupropion (2), reporting psychotic symptoms, especially delusions of reference and persecutory ideation.
Conclusion: Few cases have been described, which suggests that the appearance of these symptoms is infrequent. The synergy of dopaminergic effects or the dopaminergic sensitization in chronic consumption are the explanatory theories proposed by the authors. In these cases, a relationship was found between taking these drugs and the appearance of psychotic symptoms. Given the low number of studies found, further research is required. The risk of psychotic symptoms seems to be acceptable if we compare it with the benefits for the patients but a closer monitoring seems to be advisable.
Similar articles
-
Clinical differences between cocaine-induced psychotic disorder and psychotic symptoms in cocaine-dependent patients.Psychiatry Res. 2014 May 30;216(3):398-403. doi: 10.1016/j.psychres.2014.01.026. Epub 2014 Jan 28. Psychiatry Res. 2014. PMID: 24629712
-
[Cocaine induced psychotic disorders: a review].Rev Med Liege. 2010 Nov;65(11):623-7. Rev Med Liege. 2010. PMID: 21189528 Review. French.
-
Network analysis of psychotic manifestations among cocaine users.J Psychiatr Res. 2020 Nov;130:300-305. doi: 10.1016/j.jpsychires.2020.08.020. Epub 2020 Aug 20. J Psychiatr Res. 2020. PMID: 32866679
-
Cocaine Abuse, Traumatic Brain Injury, and Preexisting Brain Lesions as Risk Factors for Bupropion-Associated Psychosis.J Clin Psychopharmacol. 2017 Aug;37(4):459-463. doi: 10.1097/JCP.0000000000000729. J Clin Psychopharmacol. 2017. PMID: 28590371
-
An international perspective and review of cocaine-induced psychosis: a call to action.Subst Abus. 2014;35(3):321-7. doi: 10.1080/08897077.2014.933726. Subst Abus. 2014. PMID: 24927026 Review.
Cited by
-
Follow-Up of a Sample of Patients with Substance Use Disorder After Completing a Rehabilitation Program in a Continuous Care Unit in Eastern Province of Saudi Arabia, from 2012 to 2022: A Retrospective Study.Neuropsychiatr Dis Treat. 2024 Oct 9;20:1931-1939. doi: 10.2147/NDT.S473732. eCollection 2024. Neuropsychiatr Dis Treat. 2024. PMID: 39399881 Free PMC article.
-
Nanowired Delivery of Curcumin Attenuates Methamphetamine Neurotoxicity and Elevates Levels of Dopamine and Brain-Derived Neurotrophic Factor.Adv Neurobiol. 2023;32:385-416. doi: 10.1007/978-3-031-32997-5_10. Adv Neurobiol. 2023. PMID: 37480467
References
-
- Stahl S.M., Pradko J.F., Haight B.R., Modell J.G., Rockett C.B., Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim. Care Companion J. Clin. Psychiatry. 2004;6(4):159–166. [http://dx.doi.org/10.4088/PCC.v06n0403]. [PMID: 15361919]. - PMC - PubMed
-
- Corominas M., Roncero C., Casas M. Corticotropin releasing factor and neuroplasticity in cocaine addiction. Life Sci. 2010;86(1-2):1–9. [http://dx.doi.org/10.1016/j.lfs.2009.11.005]. [PMID: 19914260]. - PubMed
-
- Song X.G., Lü H., Cai X.H. Survey of studies on drug abstinence with acupuncture in recent 10 years. Zhongguo Zhenjiu. 2012;32(7):669–672. - PubMed
-
- Masana M., Bortolozzi A., Artigas F. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. Int. J. Neuropsychopharmacol. 2011;14(1):53–68. [http://dx.doi.org/10.1017/ S1461145710000908]. [PMID: 20701825]. - PubMed
-
- Williams J.M., Galli A. The dopamine transporter: a vigilant border control for psychostimulant action. Handbook Exp. Pharmacol. 2006;175:215–232. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical